Page contentsPage contents Key facts Decision Related medicine information Key facts Invented name OrenciaOrencia Active substance abatacept Therapeutic area Immunology-Rheumatology-Transplantation Decision number P/0183/2018 PIP number EMEA-000118-PIP04-17 Pharmaceutical form(s) Powder for concentrate for solution for infusionSolution for injection Route(s) of administration Intravenous useSubcutaneous use Contact for public enquiries Bristol-Myers Squibb Pharma EEIG E-mail: medical.information@bms.com Tel. +44 (0)1423 533610 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 22/06/2018 Compliance check done No Decision P/0183/2018: EMA decision of 22 June 2018 on the granting of a product specific waiver for abatacept (Orencia), (EMEA-000118-PIP04-17)Adopted Reference Number: EMA/407702/2018 English (EN) (90.72 KB - PDF)First published: 22/11/2018 View Related medicine information Orencia Share this page